Freestone Grove Partners LP Beam Therapeutics Inc. Transaction History
Freestone Grove Partners LP
- $13.2 Trillion
- Q2 2025
A detailed history of Freestone Grove Partners LP transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 11,115 shares of BEAM stock, worth $286,655. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,115Holding current value
$286,655% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BEAM
# of Institutions
246Shares Held
95.7MCall Options Held
666KPut Options Held
1.99M-
Farallon Capital Management LLC San Francisco, CA10MShares$258 Million0.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.71MShares$250 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.85MShares$228 Million1.24% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$197 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.4.73MShares$122 Million0.05% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.81B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...